Longevity Tech Radar: FDA-Cleared AI, Biomarkers, and Preventive Diagnostics
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
Latest
Research, clinical trials, regulatory updates, and industry analysis from the longevity medicine world.
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
Human Longevity Inc. partners with LEV Foundation to study blood from centenarians and supercentenarians using multi-omic analysis — seeking biomarkers that explain why some people age far more slowly.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.